Live feed07:00:00·19mPRReleasevia QuantisnowJade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026ByQuantisnow·Wall Street's wire, on your screen.JBIO· Jade Biosciences Inc.Health Care
